Skip to content

Clinical Effect and Transcriptome Study of Maitongjun'an Decoction in Treating Coronary Heart Disease of Qi Deficiency and Blood Stasis Type

Clinical Effect and Transcriptome Study of Maitongjun'an Decoction in Treating Coronary Heart Disease of Qi Deficiency and Blood Stasis Type

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073386
Enrollment
Unknown
Registered
2023-07-10
Start date
2023-07-10
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Atherosclerotic Heart Disease

Interventions

Maitong Jun'an Tang Group:On the basis of conventional Western medicine treatment, Maitong Jun'an Tang decoction should be added, 1 pack per time, twice daily, and taken separately in the morning and
Western Medicine Group:Conventional Western Medicine

Sponsors

Shanghai Traditional Chinese Medicine Hospital Cardiology Department
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Conforming to the diagnostic criteria of Western medicine for coronary heart disease; (2) Conforming to the diagnostic criteria for Qi deficiency and blood stasis syndrome in traditional Chinese medicine for coronary heart disease; (3) The age limit is between 40 and 75 years old; (4) Understand this study and be willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) The main Left coronary artery is known to have stenosis. (2) Uncontrolled hypertension or controlled systolic blood pressure = 160mmHg and/or diastolic blood pressure = 100mmHg with antihypertensive drugs. (3) Uncontrolled tachyarrhythmias that cause symptoms or hemodynamic disorders. (4) High or complete conduction block. (5) Acute Endocarditis. (6) Obstructive hypertrophic cardiomyopathy. (7) Symptomatic severe Aortic stenosis, decompensated heart failure, acute Pulmonary embolism, Deep vein thrombosis, Acute pericarditis or Myocarditis, and acute Aortic dissection. (8) Chronic lung disease is accompanied by symptoms of breathing difficulties. (9) Recent stroke or transient ischemic attack, with cognitive impairment. (10) Clinical issues that have not been corrected, such as infection, severe anemia, electrolyte disorders, hyperthyroidism, etc. (11) Patients with abnormal liver and kidney functions (Alanine transaminase or creatinine>2 times the upper limit of normal reference value). (12) Living alone is a patient who, according to the judgment of the researcher, has other pathological changes that reduce the likelihood of enrollment or complicate enrollment, as well as frequent changes in the work environment, which can easily lead to loss of follow-up. (13) I have participated in other clinical researchers within the past month. (14) In the past week, he has taken traditional Chinese medicine preparations (including traditional Chinese patent medicines and simple preparations, decoction, formula granules, etc.).

Design outcomes

Primary

MeasureTime frame
CCS angina pectoris;

Secondary

MeasureTime frame
Traditional Chinese Medicine Syndrome Points;blood fat;hsCRP;SAQ;SAS;

Countries

China

Contacts

Public ContactSun Yongning

Shanghai Municipal Hospital of Traditional Chinese Medicine affiliated to Shanghai University of Traditional Chinese Medicine

ynsun2002@126.com+86 189 3017 7579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026